Under construction – not a live service
Sign in
CompletedNo phase

Perimodiolar Implant Performance in Adults With Low-Frequency Residual Hearing

Key facts

Who runs it
Cochlear
Where
Cleveland, Kansas City, and Worcester, United StatesSee the 4 sites
Trial code
Status
Completed
People taking part
10 people enrolled
Started
16 Dec 2021
Ended
16 Jun 2025
Type of study
Interventional
Treatments tested
  • CI632 Slim Modiolar Electrode
Record updated
17 August 2026

Who can take part

Age
18 years to 69 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • 18 years-of-age or older at the time of surgery
  • Low-frequency threshold at 500 Hz ≤ 50 dB HL and high-frequency pure-tone average (PTA), 2000-8000 Hz ≥ 65 dB HL in the ear to be implanted
  • Pure-tone average (PTA) (0.5k, 1k, 2k Hz) > 30 dB HL in the contralateral ear
  • CNC word recognition scores (mean of two lists) ≤ 60% in the ear to be implanted and ≤ 80% in the contralateral ear
  • English spoken as a primary language
  • Willing and able to provide written informed consent

Who cannot take part

  • Individuals greater than or equal to 70 years at the time of surgery
  • Onset of sensorineural hearing loss, for the purpose of this study, prior to 5 years-of-age
  • Currently participating, or has participated in the last 30 days, in another interventional clinical investigation/trial involving an investigational drug or device
  • Active middle-ear infection
  • Medical or psychological conditions that contraindicate undergoing surgery as determined by the Investigator
  • Duration of severe to profound sensorineural hearing loss > 20 years per self-report
  • Ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array
  • Conductive overlay of 15 dB or greater at two or more frequencies, in the range of 250 through 1000 Hz in the ear to be implanted
  • Hearing loss of neural or central origin
  • Diagnosis of Auditory Neuropathy
  • Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the device and/or procedure, as determined by the Investigator
  • Additional handicaps that would prevent or restrict participation in the audiological evaluations as determined by the Investigator
  • Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator
  • Investigator site personnel directly affiliated with this study and/or their immediate family (spouse, parent, child, or sibling)
  • Cochlear employees or employees of a Contract Research Organization (CRO) or contractors engaged by Cochlear for the purposes of this investigation

Where in United States

  • Cleveland ClinicCleveland, United StatesNo longer taking part
  • University HospitalsCleveland, United StatesNo longer taking part
  • Midwest Ear InstituteKansas City, United StatesNo longer taking part
  • Umass Memorial Medical CenterWorcester, United StatesNo longer taking part

About the trial

What the trial wants to find out

The purpose of the feasibility study is to investigate hearing performance (audiometry and speech perception) using the CI632 in a group of adults (n=15) with low-frequency residual hearing who meet inclusion criteria.

The group in the trial

  • CI632 Slim Modiolar ElectrodeTreatment being tested

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Pre-market, Open-label Feasibility, Prospective, Single-arm Multicenter Feasibility Investigation of Hearing Performance Using the CI632 in Adults With Low-frequency Residual Hearing.
Record updated
17 August 2026